Original paper

Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy

Volume: 30, Issue: 6, Pages: 492 - 502
Published: Jun 1, 2020
Abstract
We report results from a phase 2, randomized, double-blind, 2-period trial (48 weeks each) of domagrozumab and its open-label extension in patients with Duchenne muscular dystrophy (DMD). Of 120 ambulatory boys (aged 6 to <16 years) with DMD, 80 were treated with multiple ascending doses (5, 20, and 40 mg/kg) of domagrozumab and 40 treated with placebo. The primary endpoints were safety and mean change in 4-stair climb (4SC) time at week 49....
Paper Details
Title
Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy
Published Date
Jun 1, 2020
Volume
30
Issue
6
Pages
492 - 502
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.